Departement
Klinische Forschung
Achtung: Diese Seite kann nur von Administratoren besucht werden, da Sie nicht freigeschalten wurde.
Zurück
Publications Derfuss Tobias Johannes

All Bruton's tyrosine kinase inhibitors have similar efficacy and risks: Commentary.

Yaldizli Ö; Derfuss T. Multiple Sclerosis Journal. 2022.

Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis.

Cagol A; Schaedelin S; Barakovic M; Benkert P; Todea RA; Rahmanzadeh R; Galbusera R; Lu PJ; Weigel M; Melie-Garcia L; Ruberte E; Siebenborn N; Battaglini M; Radue EW; Yaldizli Ö; Oechtering J; Sinnecker T; Lorscheider J; Fischer-Barnicol B; Müller S; Achtnichts L; Vehoff J; Disanto G; Findling O; Chan A; Salmen A; Pot C; Bridel C; Zecca C; Derfuss T; Lieb JM; Remonda L; Wagner F; Vargas MI; Du Pasquier R; Lalive PH; Pravatà E; Weber J; Cattin PC; Gobbi C; Leppert D; Kappos L; Kuhle J; Granziera C. JAMA Neurology. 2022.

Brain atrophy measurement over a MRI scanner change in multiple sclerosis.

Sinnecker T; Schädelin S; Benkert P; Ruberte E; Amann M; Lieb JM; Naegelin Y; Müller J; Kuhle J; Derfuss T; Kappos L; Wuerfel J; Granziera C; Yaldizli Ö. NeuroImage. Clinical. 2022.

Choroid Plexus Volume in Multiple Sclerosis vs Neuromyelitis Optica Spectrum Disorder: A Retrospective, Cross-sectional Analysis.

Müller J; Sinnecker T; Wendebourg MJ; Schläger R; Kuhle J; Schädelin S; Benkert P; Derfuss T; Cattin P; Jud C; Spiess F; Amann M; Lincke T; Barakovic M; Cagol A; Tsagkas C; Parmar K; Pröbstel AK; Reimann S; Asseyer S; Duchow A; Brandt A; Ruprecht K; Hadjikhani N; Fukumoto S; Watanabe M; Masaki K; Matsushita T; Isobe N; Kira JI; Kappos L; Würfel J; Granziera C; Paul F; Yaldizli Ö. Neurology(R) neuroimmunology & neuroinflammation. 2022.

Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis

Filippi M.; Danesi R.; Derfuss T.; Duddy M.; Gallo P.; Gold R.; Havrdova E.K.; Kornek B.; Sacca F.; Tintore M.; Weber J.; Trojano M.. Journal of Neurology. 2022.

Early Reduction of MRI Activity During 6 Months of Treatment With Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis: MAGNIFY-MS.

de Stefano N; Barkhof F; Montalban X; Achiron A; Derfuss T; Chan A; Hodgkinson S; Prat A; Leocani L; Schmierer K; Sellebjerg F; Vermersch P; Wiendl H; Keller B; Roy S; MAGNIFY-MS Study Group. Neurology(R) neuroimmunology & neuroinflammation. 2022.

Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study.

Hartung HP; Derfuss T; Cree BA; Sormani MP; Selmaj K; Stutters J; Prados F; MacManus D; Schneble HM; Lambert E; Porchet H; Glanzman R; Warne D; Curtin F; Kornmann G; Buffet B; Kremer D; Küry P; Leppert D; Rückle T; Barkhof F. Multiple Sclerosis Journal. 2022.

High-dimensional immune profiling identifies a biomarker to monitor dimethyl fumarate response in multiple sclerosis.

Diebold M; Galli E; Kopf A; Sanderson NSR; Callegari I; Benkert P; Gonzalo Núñez N; Ingelfinger F; Herms S; Cichon S; Kappos L; Kuhle J; Becher B; Claassen M; Derfuss T. Proceedings of the National Academy of Sciences of the United States of America. 2022.

Immunological Predictors of Dimethyl Fumarate-Induced Lymphopenia.

Diebold M; Galli E; Kopf A; Sanderson N; Callegari I; Ingelfinger F; Núñez NG; Benkert P; Kappos L; Kuhle J; Becher B; Claassen M; Derfuss T. Annals of Neurology. 2022.

Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey

Portaccio E.; Fonderico M.; Hemmer B.; Derfuss T.; Stankoff B.; Selmaj K.; Tintore M.; Amato M.P.. Multiple Sclerosis Journal. 2022.

Intrathecal IgM Synthesis Is Associated with Spinal Cord Manifestation and Neuronal Injury in Early MS.

Oechtering J; Lincke T; Schaedelin S; Décard BF; Maceski A; Orleth A; Meier S; Willemse E; Buchmann A; Khalil M; Derfuss T; Benkert P; Heijnen I; Regeniter A; Müller S; Achtnichts L; Lalive P; Salmen A; Pot C; Gobbi C; Kappos L; Granziera C; Leppert D; Schlaeger R; Lieb JM; Kuhle J; Swiss MS Cohort Study. Annals of Neurology. 2022.

Normal B-cell ranges in infants: A systematic review and meta-analysis.

Borriello F; Pasquarelli N; Law L; Rand K; Raposo C; Wei W; Craveiro L; Derfuss T. Journal of Allergy and Clinical Immunology. 2022.

Potent neutralization by monoclonal human IgM against SARS-CoV-2 is impaired by class switch.

Callegari I; Schneider M; Berloffa G; Mühlethaler T; Holdermann S; Galli E; Roloff T; Boss R; Infanti L; Khanna N; Egli A; Buser A; Zimmer G; Derfuss T; Sanderson NSR. EMBO Reports. 2022.

Receptor clustering and pathogenic complement activation in myasthenia gravis depend on synergy between antibodies with multiple subunit specificities.

Rose N; Holdermann S; Callegari I; Kim H; Fruh I; Kappos L; Kuhle J; Müller M; Sanderson NSR; Derfuss T. Acta Neuropathologica. 2022.

Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study.

Benkert P; Meier S; Schaedelin S; Manouchehrinia A; Yaldizli Ö; Maceski A; Oechtering J; Achtnichts L; Conen D; Derfuss T; Lalive PH; Mueller C; Müller S; Naegelin Y; Oksenberg JR; Pot C; Salmen A; Willemse E; Kockum I; Blennow K; Zetterberg H; Gobbi C; Kappos L; Wiendl H; Berger K; Sormani MP; Granziera C; Piehl F; Leppert D; Kuhle J; NfL Reference Database in the Swiss Multiple Sclerosis Cohort Study Group. The Lancet Neurology. 2022.

The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021.

Tur C; Dubessy AL; Otero-Romero S; Amato MP; Derfuss T; Di Pauli F; Iacobaeus E; Mycko M; Abboud H; Achiron A; Bellinvia A; Boyko A; Casanova JL; Clifford D; Dobson R; Farez MF; Filippi M; Fitzgerald KC; Fonderico M; Gouider R; Hacohen Y; Hellwig K; Hemmer B; Kappos L; Ladeira F; Lebrun-Frénay C; Louapre C; Magyari M; Mehling M; Oreja-Guevara C; Pandit L; Papeix C; Piehl F; Portaccio E; Ruiz-Camps I; Selmaj K; Simpson-Yap S; Siva A; Sorensen PS; Sormani MP; Trojano M; Vaknin-Dembinsky A; Vukusic S; Weinshenker B; Wiendl H; Winkelmann A; Zuluaga Rodas MI; Tintoré M; Stankoff B. Multiple Sclerosis Journal. 2022.

Alcohol consumption and neurocognitive deficits in people with well-treated HIV in Switzerland

Darling K.E.A.; Locatelli I.; Benghalem N.; Nadin I.; Calmy A.; Gutbrod K.; Hauser C.; Brugger P.; Hasse B.; Kovari H.; Kunze U.; Stoeckle M.; Fux C.; Rossi S.; Di Benedetto C.; Fruh S.; Schmid P.; Tarr P.E.; Daeppen J.-B.; Pasquier R.D.; Cavassini M.; Metral M.; Simioni S.; Monsch A.U.; Schneitter M.; Schwind M.; Pignatti R.; Clarke S.; Assal F.; Derfuss T.; von Arx S.; Jelcic I.; Sacco L.; Bertschi M.; Hundsberger T.; Lecompte T.D.; Cusini A.; Bernasconi E.; Bruno A.; Scherrer A.; Vallet Y.; Alves D.; Decosterd L.; Granziera C.; Krueger G.; Meuli R.; Vargas M.; Aebi-Popp K.; Anagnostopoulos A.; Battegay M.; Boni J.; Braun D.L.; Bucher H.C.; Ciuffi A.; Dollenmaier G.; Egger M.; Elzi L.; Fehr J.; Fellay J.; Furrer H.; Gunthard H.F.; Haerry D.; Hirsch H.H.; Hoffmann M.; Hosli I.; Huber M.; Kahlert C.R.; Kaiser L.; Keiser O.; Klimkait T.; Kouyos R.D.; Ledergerber B.; Martinetti G.; Martinez de Tejada B.; Marzolini C.; Metzner K.J.; Muller N.; Nicca D.; Paioni P.; Pantaleo G.; Perreau M.; Rauch A.; Rudin C.; Speck R.; Stockle M.; Trkola A.; Vernazza P.; Wandeler G.; Yerly S.. PLoS ONE. 2021.

Characteristics of improvements in balance control using vibro-tactile biofeedback of trunk sway for multiple sclerosis patients.

Allum JHJ; Rust HM; Lutz N; Schouenborg C; Fischer-Barnicol B; Haller V; Derfuss T; Kuhle J; Yaldizli Ö. Journal of the neurological sciences. 2021.

Combination of teriflunomide and interferon as follow-up therapy after fingolimod-associated PML

Fischer-Barnicol B.; Oechtering J.; Kuhle J.; Lorscheider J.; Kappos L.; Derfuss T.. Neurology(R) neuroimmunology & neuroinflammation. 2021.

Comparative analysis of dimethyl fumarate and fingolimod in relapsing-remitting multiple sclerosis.

Lorscheider J; Benkert P; Lienert C; Hänni P; Derfuss T; Kuhle J; Kappos L; Yaldizli Ö. Journal of Neurology. 2021.

Dimethyl fumarate treatment restrains the antioxidative capacity of T cells to control autoimmunity.

Liebmann M; Korn L; Janoschka C; Albrecht S; Lauks S; Herrmann AM; Schulte-Mecklenbeck A; Schwab N; Schneider-Hohendorf T; Eveslage M; Wildemann B; Luessi F; Schmidt S; Diebold M; Bittner S; Gross CC; Kovac S; Zipp F; Derfuss T; Kuhlmann T; König S; Meuth SG; Wiendl H; Klotz L. Brain. 2021.

Disability progression in relapse-free multiple sclerosis patients on fingolimod versus interferon-beta/glatiramer acetate.

von Wyl V; Benkert P; Moser A; Lorscheider J; Décard B; Hänni P; Lienert C; Kuhle J; Derfuss T; Kappos L; Yaldizli Ö. Multiple Sclerosis Journal. 2021.

Intrathecal Immunoglobulin M Synthesis is an Independent Biomarker for Higher Disease Activity and Severity in Multiple Sclerosis.

Oechtering J; Schaedelin S; Benkert P; Müller S; Achtnichts L; Vehoff J; Disanto G; Findling O; Fischer-Barnicol B; Orleth A; Chan A; Pot C; Barakovic M; Rahmanzadeh R; Galbusera R; Heijnen I; Lalive PH; Wuerfel J; Subramaniam S; Aeschbacher S; Conen D; Naegelin Y; Maceski A; Meier S; Berger K; Wiendl H; Lincke T; Lieb J; Yaldizli Ö; Sinnecker T; Derfuss T; Regeniter A; Zecca C; Gobbi C; Kappos L; Granziera C; Leppert D; Kuhle J; Swiss Multiple Sclerosis Cohort Study. Annals of Neurology. 2021.

Mass Cytometry of CSF Identifies an MS-Associated B-cell Population.

Johansson D; Rauld C; Roux J; Regairaz C; Galli E; Callegari I; Raad L; Waldt A; Cuttat R; Roma G; Diebold M; Becher B; Kuhle J; Derfuss T; Carballido JM; Sanderson NSR. Neurology(R) neuroimmunology & neuroinflammation. 2021.

Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)

Wiendl H.; Gold R.; Berger T.; Derfuss T.; Linker R.; Maurer M.; Aktas O.; Baum K.; Berghoff M.; Bittner S.; Chan A.; Czaplinski A.; Deisenhammer F.; Di Pauli F.; Du Pasquier R.; Enzinger C.; Fertl E.; Gass A.; Gehring K.; Gobbi C.; Goebels N.; Guger M.; Haghikia A.; Hartung H.-P.; Heidenreich F.; Hoffmann O.; Kallmann B.; Kleinschnitz C.; Klotz L.; Leussink V.I.; Leutmezer F.; Limmroth V.; Lunemann J.D.; Lutterotti A.; Meuth S.G.; Meyding-Lamade U.; Platten M.; Rieckmann P.; Schmidt S.; Tumani H.; Weber F.; Weber M.S.; Zettl U.K.; Ziemssen T.; Zipp F.. Therapeutic advances in neurological disorders. 2021.

Multiple sclerosis treatment consensus group (MSTCG): position paper on disease-modifying treatment of multiple sclerosis 2021 (white paper) Multiple Sklerose Therapie Konsensus Gruppe (MSTKG): Positionspapier zur verlaufsmodifizierenden Therapie der Multiplen Sklerose 2021 (White Paper)

Wiendl H.; Gold R.; Berger T.; Derfuss T.; Linker R.; Maurer M.; Stangel M.; Aktas O.; Baum K.; Berghoff M.; Bittner S.; Chan A.; Czaplinski A.; Deisenhammer F.; DiPauli F.; DuPasquier R.; Enzinger C.; Fertl E.; Gass A.; Gehring K.; Gobbi C.; Goebels N.; Guger M.; Haghikia A.; Hartung H.-P.; Heidenreich F.; Hoffmann O.; Hunter Z.R.; Kallmann B.; Kleinschnitz C.; Klotz L.; Leussink V.; Leutmezer F.; Limmroth V.; Lunemann J.D.; Lutterotti A.; Meuth S.G.; Meyding-Lamade U.; Platten M.; Rieckmann P.; Schmidt S.; Tumani H.; Weber M.S.; Weber F.; Zettl U.K.; Ziemssen T.; Zipp F.. Nervenarzt. 2021.

Myelin-oligodendrocyte glycoprotein antibody-associated disease

Marignier R.; Hacohen Y.; Cobo-Calvo A.; Probstel A.-K.; Aktas O.; Alexopoulos H.; Amato M.-P.; Asgari N.; Banwell B.; Bennett J.; Brilot F.; Capobianco M.; Chitnis T.; Ciccarelli O.; Deiva K.; De Seze J.; Fujihara K.; Jacob A.; Kim H.J.; Kleiter I.; Lassmann H.; Leite M.-I.; Linington C.; Meinl E.; Palace J.; Paul F.; Petzold A.; Pittock S.; Reindl M.; Sato D.K.; Selmaj K.; Siva A.; Stankoff B.; Tintore M.; Traboulsee A.; Waters P.; Waubant E.; Weinshenker B.; Derfuss T.; Vukusic S.; Hemmer B.. The Lancet Neurology. 2021.

The association between depressive symptoms and neurocognitive impairment in people with well-treated HIV in Switzerland

Santos G.; Locatelli I.; Metral M.; Berney A.; Nadin I.; Calmy A.; Tarr P.; Gutbrod K.; Hauser C.; Brugger P.; Kovari H.; Kunze U.; Stoeckle M.; Fruh S.; Schmid P.; Rossi S.; Di Benedetto C.; Du Pasquier R.; Darling K.; Cavassini M.; Simioni S.; Monsch A.U.; Schneitter M.; Schwind M.; Pignatti R.; Clarke S.; Assal F.; Derfuss T.; von Arx S.; Eisele G.; Sacco L.; Bertschi M.; Hundsberger T.; Lecompte T.D.; Cusini A.; Weber R.; Hasse B.; Fux C.; Bernasconi E.; Scherrer A.; Vallet Y.; Alves D.; Decosterd L.; Granziera C.; Krueger G.; Meuli R.; Vargas M.; Aebi-Popp K.; Anagnostopoulos A.; Battegay M.; Boni J.; Braun D.L.; Bucher H.C.; Calmy A.; Cavassini M.; Ciuffi A.; Dollenmaier G.; Egger M.; Elzi L.; Fehr J.; Fellay J.; Furrer H.; Gunthard H.F.; Haerry D.; Hirsch H.H.; Hoffmann M.; Hosli I.; Huber M.; Kahlert C.R.; Kaiser L.; Keiser O.; Klimkait T.; Kouyos R.D.; Kovari H.; Ledergerber B.; Martinetti G.; de Tejada B.M.; Marzolini C.; Metzner K.J.; Muller N.; Nicca D.; Paioni P.; Pantaleo G.; Perreau M.; Rauch A.; Rudin C.; Schmid P.; Speck R.; Stockle M.; Trkola A.; Vernazza P.; Wandeler G.; Yerly S.. International Journal of STD and AIDS. 2021.

Update on treatment in multiple sclerosis

Callegari I.; Derfuss T.; Galli E.. Presse medicale (Paris, France : 1983). 2021.

Advances in oral immunomodulating therapies in relapsing multiple sclerosis.

Derfuss T; Mehling M; Papadopoulou A; Bar-Or A; Cohen JA; Kappos L. The Lancet Neurology. 2020.

Aggressive multiple sclerosis (1): Towards a definition of the phenotype

Iacobaeus E.; Arrambide G.; Amato M.P.; Derfuss T.; Vukusic S.; Hemmer B.; Tintore M.; Brundin L.; Berger J.; Boyko A.; Brinar V.; Brownlee W.; Ciccarelli O.; Coles A.; Correale J.; Cutter G.; Edan G.; Evangelou N.; Fernandez O.; Frederiksen J.; Gold R.; Hacohen Y.; Hartung H.-P.; Hellwig K.; Hillert J.; Imitola J.; Kalincik T.; Kappos L.; Khoury S.; Kim H.J.; Havrdova E.K.; Liblau R.; Lycke J.; Montalban X.; Muraro P.; Reingold S.; Schmierer K.; Sellebjerg F.; Sorensen P.S.; Solari A.; Sormani M.P.; Thompson A.; Trapp B.; Tremlett H.; Trojano M.; Tur C.; Uccelli A.; van Pesch V.; Waubant E.. Multiple Sclerosis Journal. 2020.

Aggressive multiple sclerosis (2): Treatment

Arrambide G.; Iacobaeus E.; Amato M.P.; Derfuss T.; Vukusic S.; Hemmer B.; Brundin L.; Tintore M.; Berger J.; Boyko A.; Brinar V.; Brownlee W.; Ciccarelli O.; Coles A.; Correale J.; Cutter G.; Edan G.; Evangelou N.; Fernandez O.; Frederiksen J.; Gold R.; Hacohen Y.; Hartung H.-P.; Hellwig K.; Hillert J.; Imitola J.; Kalincik T.; Kappos L.; Khoury S.; Kim H.J.; Havrdova E.K.; Liblau R.; Lycke J.; Montalban X.; Muraro P.; Reingold S.; Schmierer K.; Sellebjerg F.; Sorensen P.S.; Solari A.; Sormani M.P.; Thompson A.; Trapp B.; Tremlett H.; Trojano M.; Tur C.; Uccelli A.; van Pesch V.; Waubant E.. Multiple Sclerosis Journal. 2020.

Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium.

Hässler S; Bachelet D; Duhaze J; Szely N; Gleizes A; Hacein-Bey Abina S; Aktas O; Auer M; Avouac J; Birchler M; Bouhnik Y; Brocq O; Buck-Martin D; Cadiot G; Carbonnel F; Chowers Y; Comabella M; Derfuss T; De Vries N; Donnellan N; Doukani A; Guger M; Hartung HP; Kubala Havrdova E; Hemmer B; Huizinga T; Ingenhoven K; Hyldgaard-Jensen PE; Jury EC; Khalil M; Kieseier B; Laurén A; Lindberg R; Loercher A; Maggi E; Manson J; Mauri C; Mohand Oumoussa B; Montalban X; Nachury M; Nytrova P; Richez C; Ryner M; Sellebjerg F; Sievers C; Sikkema D; Soubrier M; Tourdot S; Trang C; Vultaggio A; Warnke C; Spindeldreher S; Dönnes P; Hickling TP; Hincelin Mery A; Allez M; Deisenhammer F; Fogdell-Hahn A; Mariette X; Pallardy M; Broët P; ABIRISK consortium. PLoS Medicine. 2020.

How helpful are the European AIDS Clinical Society cognitive screening questions in predicting cognitive impairment in an aging, well-treated HIV-positive population?

Metral M.; Nadin I.; Locatelli I.; Tarr P.E.; Calmy A.; Kovari H.; Brugger P.; Cusini A.; Gutbrod K.; Schmid P.; Schwind M.; Kunze U.; Di Benedetto C.; Pignatti R.; Du Pasquier R.; Darling K.E.A.; Cavassini M.; Cavassini M.; Pasquier R.D.; Metral M.; Simioni S.; Brugger P.; Gutbrod K.; Monsch A.U.; Kunze U.; Schneitter M.; Nadin I.; Fruh S.; Schwind M.; Pignatti R.; Clarke; S.; Assal F.; Derfuss T.; von Arx S.; Eisele G.; Sacco L.; Bertschi M.; Hundsberger T.; Pasquier R.D.; Calmy A.; Doco Lecompte T.; Hauser C.; Cusini A.; Weber R.; Kovari H.; Hasse B.; Stoeckle M.; Fux C.; Bernasconi E.; Di Benedetto C.; Bruno A.; Schmid P.; Darling K.; Cavassini M.; Scherrer A.; Scherrer A.; Vallet Y.; Alves D.; Locatelli; I.; Decosterd L.; Granziera C.; Krueger G.; Meuli R.; Vargas M.; Aebi-Popp K.; Anagnostopoulos A.; Battegay M.; Bernasconi E.; Boni J.; Braun D.L.; Bucher H.C.; Calmy A.; Cavassini M.; Ciuffi A.; Dollenmaier G.; Egger M.; Elzi L.; Fehr J.; Fellay J.; Furrer H.; Fux C.A.; Gunthard H.F.; Haerry D.; Hasse B.; Hirsch H.H.; Hoffmann M.; Hosli I.; Huber M.; Kahlert C.R.; Kaiser L.; Keiser O.; Klimkait T.; Kouyos R.D.; Kovari H.; Ledergerber B.; Martinetti G.; Martinez de Tejada B.; Marzolini C.; Metzner K.J.; Muller N.; Nicca D.; Paioni P.; Pantaleo G.; Perreau M.; Rauch A.; Rudin C.; Scherrer A.U.; Schmid P.; Speck R.; Stockle M.; Trkola A.; Vernazza P.; Wandeler G.; Weber R.; Yerly S.. HIV Medicine. 2020.

Influence of age at disease onset on future relapses and disability progression in patients with multiple sclerosis on immunomodulatory treatment.

von Wyl V; Décard BF; Benkert P; Lorscheider J; Hänni P; Lienert C; Kuhle J; Derfuss T; Kappos L; Yaldizli Ö. European Journal of Neurology. 2020.

Lymphocyte recovery after fingolimod discontinuation in patients with MS.

Nagy S; Kuhle J; Derfuss T. Neurology(R) neuroimmunology & neuroinflammation. 2020.

Magnetic resonance imaging in immune-mediated myelopathies.

Wendebourg MJ; Nagy S; Derfuss T; Parmar K; Schlaeger R. Journal of Neurology. 2020.

New and enlarging white matter lesions adjacent to the ventricle system and thalamic atrophy are independently associated with lateral ventricular enlargement in multiple sclerosis.

Sinnecker T; Ruberte E; Schädelin S; Canova V; Amann M; Naegelin Y; Penner IK; Müller J; Kuhle J; Décard B; Derfuss T; Kappos L; Granziera C; Wuerfel J; Magon S; Yaldizli Ö. Journal of Neurology. 2020.

Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial

Cree B.; Cutter G.; Wolinsky J.S.; Freedman M.; Comi G.; Giovannoni G.; Hartung H.-P.; Arnold D.; Kuhle J.; Block V.; Munschauer F.E.; Sedel F.; Lublin F.D.; Reingold S.; Duquette P.; Derfuss T.; Fazekas F.; Sormani M.P.; Lisak R.P.; Graves J.; Krieger S.; Zabad R.K.; Newsome S.; Barton J.; MacDonell R.; Marriott M.; De Klippel N.; Laureys G.; Willekens B.; Devonshire V.; Freedman M.; Girard J.M.; Giacomini P.; McKelvey R.; Selchen D.; Vorobeychik G.; Witkowski L.; Ampapa R.; Preiningerova J.L.; Meluzinova E.; Talab R.; Vachova M.; Aktas O.; Buttmann M.; Birte E.-H.; Kuempfel T.; Friedemann P.; Rau D.; Reifschneider G.; Sokolowski P.; Tumani H.; Satori M.; Pozzilli C.; Klosek A.; Koscielniak J.; Waldemar F.; Zajda M.; Gonzalez R.A.; Ayuso G.I.; Sanchez V.F.; Guevara C.O.; Rodriguez J.E.M.; Montalban X.; Ramio-Torrenta L.; Brundin L.; Lycke J.; Terzi M.; Guadagno J.; Mahad D.; Pace A.; Schmierer K.; Toosy A.; Webb S.; Agius M.; Amezcua L.; Apperson M.; Bagert B.; Bandari D.; Bernitsas E.; Calkwood J.; Carter J.; Cohen B.; Conway D.; Cooper J.; Corboy J.; Coyle P.; Cree B.; Freedman M.; Ford C.; Fox E.; Goldman M.; Greenberg B.; Kita M.; Leist T.; Lynch S.; Miller A.; Moses H.; Naismith R.; Picone M.A.; Perminder B.; Rae-Grant A.; Rammohan K.; Reder A.; Riley C.; Robertson D.; Rowe V.; Saidha S.; Samkoff L.; Severson C.; Smoot K.; Stoll S.; Trudell R.; Weinstock-Guttman B.; Yathiraj S.. The Lancet Neurology. 2020.

Selective inhibition of anti-MAG IgM autoantibody binding to myelin by an antigen-specific glycopolymer.

Aliu B; Demeestere D; Seydoux E; Boucraut J; Delmont E; Brodovitch A; Oberholzer T; Attarian S; Théaudin M; Tsouni P; Kuntzer T; Derfuss T; Steck AJ; Ernst B; Herrendorff R; Hänggi P. Journal of neurochemistry. 2020.

The ACROSS study: Long-term efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis.

Derfuss T; Sastre-Garriga J; Montalban X; Rodegher M; Wuerfel J; Gaetano L; Tomic D; Azmon A; Wolf C; Kappos L. Multiple sclerosis journal - experimental, translational and clinical. 2020.

The Neurocognitive Assessment in the Metabolic and Aging Cohort (NAMACO) study: baseline participant profile

Metral M.; Darling K.E.A.; Locatelli I.; Nadin I.; Santos G.; Brugger P.; Kovari H.; Cusini A.; Gutbrod K.; Tarr P.E.; Calmy A.; Lecompte T.D.; Assal F.; Monsch A.U.; Kunze U.; Stoeckle M.; Schwind M.; Schmid P.; Pignatti R.; Di Benedetto C.; Du Pasquier R.; Cavassini M.; Cavassini M.; Du Pasquier R.; Metral M.; Simioni S.; Brugger P.; Gutbrod K.; Monsch A.U.; Kunze U.; Schneitter M.; Nadin I.; Fruh S.; Schwind M.; Pignatti R.; Clarke S.; Assal F.; Derfuss T.; von Arx S.; Eisele G.; Sacco L.; Bertschi M.; Hundsberger T.; Du Pasquier R.; Calmy A.; Hauser C.; Cusini A.; Weber R.; Kovari H.; Hasse B.; Stoeckle M.; Fux C.; Bernasconi E.; Di Benedetto C.; Bruno A.; Schmid P.; Darling K.; Cavassini M.; Scherrer A.; Scherrer A.; Vallet Y.; Alves D.; Locatelli I.; Decosterd L.; Granziera C.; Krueger G.; Meuli R.; Vargas M.. HIV Medicine. 2020.

A case of concomitant psoriasis and multiple sclerosis: Secukinumab and rituximab exert dichotomous effects in two autoimmune conditions.

Diebold M; Müller S; Derfuss T; Décard BF. Multiple Sclerosis and Related Disorders. 2019.

A case of progressive multifocal leukoencephalopathy under dimethyl fumarate treatment without severe lymphopenia or immunosenescence.

Diebold M; Altersberger V; Décard BF; Kappos L; Derfuss T; Lorscheider J. Multiple Sclerosis Journal. 2019.

Antigen Extraction and B Cell Activation Enable Identification of Rare Membrane Antigen Specific Human B Cells.

Zimmermann M; Rose N; Lindner JM; Kim H; Gonçalves AR; Callegari I; Syedbasha M; Kaufmann L; Egli A; Lindberg RLP; Kappos L; Traggiai E; Sanderson NSR; Derfuss T. Frontiers in Immunology. 2019.

Association of antibodies against myelin and neuronal antigens with neuroinflammation in systemic lupus erythematosus.

Pröbstel AK; Thanei M; Erni B; Lecourt AC; Branco L; André R; Roux-Lombard P; Koenig KF; Huynh-Do U; Ribi C; Chizzolini C; Kappos L; Trendelenburg M; Derfuss T; Swiss Systemic Lupus Erythematosus Cohort Study Group. Rheumatology (United Kingdom). 2019.

Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis.

Naegelin Y; Naegelin P; von Felten S; Lorscheider J; Sonder J; Uitdehaag BMJ; Scotti B; Zecca C; Gobbi C; Kappos L; Derfuss T. JAMA Neurology. 2019.

Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study.

Jensen PEH; Warnke C; Ingenhoven K; Piccoli L; Gasis M; Hermanrud C; Fernandez-Rodriguez BM; Ryner M; Kramer D; Link J; Ramanujam R; Auer M; Buck D; Grummel V; Bertotti E; Fissolo N; Oliver-Martos B; Nytrova P; Khalil M; Guger M; Rathmaier S; Sievers-Stober C; Lindberg RLP; Hässler S; Bachelet D; Aktas O; Donnellan N; Lawton A; Hemmer B; Havrdova EK; Kieseier B; Hartung HP; Comabella M; Montalban X; Derfuss T; Sellebjerg F; Dönnes P; Pallardy M; Spindeldreher S; Broët P; Deisenhammer F; Fogdell-Hahn A; Sorensen PS; ABIRISK Consortium.. Journal of Neuroimmunology. 2019.

GM-CSF and CXCR4 define a T helper cell signature in multiple sclerosis.

Galli E; Hartmann FJ; Schreiner B; Ingelfinger F; Arvaniti E; Diebold M; Mrdjen D; van der Meer F; Krieg C; Nimer FA; Sanderson N; Stadelmann C; Khademi M; Piehl F; Claassen M; Derfuss T; Olsson T; Becher B. Nature Medicine. 2019.

Hepatitis E virus infections in patients with MS on oral disease-modifying treatment.

Diebold M; Fischer-Barnicol B; Tsagkas C; Kuhle J; Kappos L; Derfuss T; Décard BF. Neurology(R) neuroimmunology & neuroinflammation. 2019.

PARP-1 deregulation in multiple sclerosis.

Meira M; Sievers C; Hoffmann F; Bodmer H; Derfuss T; Kuhle J; Haghikia A; Kappos L; Lindberg RL. Multiple sclerosis journal - experimental, translational and clinical. 2019.

PML with dimethyl fumarate-No convincing case against natalizumab.

Diebold M; Altersberger V; Décard BF; Kappos L; Derfuss T; Lorscheider J. Multiple Sclerosis Journal. 2019.

Quantitative 7T MRI does not detect occult brain damage in neuromyelitis optica.

Pasquier B; Borisow N; Rasche L; Bellmann-Strobl J; Ruprecht K; Niendorf T; Derfuss TJ; Wuerfel J; Paul F; Sinnecker T. Neurology(R) neuroimmunology & neuroinflammation. 2019.

The monoclonal antibody GNbAC1: targeting human endogenous retroviruses in multiple sclerosis.

Diebold M; Derfuss T. Therapeutic advances in neurological disorders. 2019.

Anti-Myelin Oligodendrocyte Glycoprotein Antibody-Associated Central Nervous System Demyelination-A Novel Disease Entity?

Weber MS; Derfuss T; Brück W. JAMA Neurology. 2018.

Central Slab versus Whole Brain to Measure Brain Atrophy in Multiple Sclerosis.

Ruberte E; Sinnecker T; Amann M; Gaetano L; Naegelin Y; Penner IK; Kuhle J; Derfuss T; Kappos L; Granziera C; Wuerfel J; Yaldizli Ö. European Neurology. 2018.

Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis.

Lorscheider J; Benkert P; Lienert C; Hänni P; Derfuss T; Kuhle J; Kappos L; Yaldizli Ö. Multiple Sclerosis Journal. 2018.

Defining distinct features of anti-MOG antibody associated central nervous system demyelination.

Weber MS; Derfuss T; Metz I; Brück W. Therapeutic advances in neurological disorders. 2018.

Dimethyl fumarate influences innate and adaptive immunity in multiple sclerosis

Diebold M.; Sievers C.; Bantug G.; Sanderson N.; Kappos L.; Kuhle J.; Lindberg R.L.P.; Derfuss T.. Journal of Autoimmunity. 2018.

ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis.

Montalban X; Gold R; Thompson AJ; Otero-Romero S; Amato MP; Chandraratna D; Clanet M; Comi G; Derfuss T; Fazekas F; Hartung HP; Havrdova E; Hemmer B; Kappos L; Liblau R; Lubetzki C; Marcus E; Miller DH; Olsson T; Pilling S; Selmaj K; Siva A; Sorensen PS; Sormani MP; Thalheim C; Wiendl H; Zipp F. European Journal of Neurology. 2018.

ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis.

Montalban X; Gold R; Thompson AJ; Otero-Romero S; Amato MP; Chandraratna D; Clanet M; Comi G; Derfuss T; Fazekas F; Hartung HP; Havrdova E; Hemmer B; Kappos L; Liblau R; Lubetzki C; Marcus E; Miller DH; Olsson T; Pilling S; Selmaj K; Siva A; Sorensen PS; Sormani MP; Thalheim C; Wiendl H; Zipp F. Multiple Sclerosis Journal. 2018.

Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop.

Amato MP; Derfuss T; Hemmer B; Liblau R; Montalban X; Soelberg Sørensen P; Miller DH; 2016 ECTRIMS Focused Workshop Group. Multiple Sclerosis Journal. 2018.

Extensive bilateral brain lesions in neuromyelitis optica spectrum disorders.

Décard BF; Derfuss T. . 2018.

Serum neurofilament light chain: a biomarker of neuronal injury in vasculitic neuropathy.

Bischof A; Manigold T; Barro C; Heijnen I; Berger CT; Derfuss T; Kuhle J; Daikeler T. Annals of the Rheumatic Diseases. 2018.

Shortening the washout to 4 weeks when switching from natalizumab to fingolimod and risk of disease reactivation in multiple sclerosis.

Naegelin Y; Rasenack M; Andelova M; Von Felten S; Fischer-Barnicol B; Amann M; Mehling M; Kappos L; Sprenger T; Derfuss T. Multiple Sclerosis and Related Disorders. 2018.

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Kappos L.; Bar-Or A.; Cree B.A.C.; Fox R.J.; Giovannoni G.; Gold R.; Vermersch P.; Arnold D.L.; Arnould S.; Scherz T.; Wolf C.; Wallstrom E.; Dahlke F.; Achiron A.; Achtnichts L.; Agan K.; Akman-Demir G.; Allen A.B.; Antel J.P.; Antiguedad A.R.; Apperson M.; Applebee A.M.; Ayuso G.I.; Baba M.; Bajenaru O.; Balasa R.; Balci B.P.; Barnett M.; Bass A.; Becker V.U.; Bejinariu M.; Bergh F.T.; Bergmann A.; Bernitsas E.; Berthele A.; Bhan V.; Bischof F.; Bjork R.J.; Blevins G.; Boehringer M.; Boerner T.; Bonek R.; Bowen J.D.; Bowling A.; Boyko A.N.; Boz C.; Bracknies V.; Braune S.; Brescia Morra V.; Brochet B.; Brola W.; Brownstone P.K.; Brozman M.; Brunet D.; Buraga I.; Burnett M.; Buttmann M.; Butzkueven H.; Cahill J.; Calkwood J.C.; Camu W.; Cascione M.; Castelnovo G.; Centonze D.; Cerqueira J.; Chan A.; Cimprichova A.; Cohan S.; Comi G.; Conway J.; Cooper J.A.; Corboy J.; Correale J.; Costell B.; Cottrell D.A.; Coyle P.K.; Craner M.; Cui L.; Cunha L.; Czlonkowska A.; da Silva A.M.; de Sa J.; de Seze J.; Debouverie M.; Debruyne J.; Decoo D.; Defer G.; Derfuss T.; Deri N.H.; Dihenia B.; Dioszeghy P.; Donath V.; Dubois B.; Duddy M.; Duquette P.; Edan G.; Efendi H.; Elias S.; Emrich P.J.; Estruch B.C.; Evdoshenko E.P.; Faiss J.; Fedyanin A.S.; Feneberg W.; Fermont J.; Fernandez O.F.; Ferrer F.C.; Fink K.; Ford H.; Ford C.; Francia A.; Freedman M.; Frishberg B.; Galgani S.; Garmany G.P.; Gehring K.; Gitt J.; Gobbi C.; Goldstick L.P.; Gonzalez R.A.; Grandmaison F.; Grigoriadis N.; Grigorova O.; Grimaldi L.M.E.; Gross J.; Gross-Paju K.; Gudesblatt M.; Guillaume D.; Haas J.; Hancinova V.; Hancu A.; Hardiman O.; Harmjanz A.; Heidenreich F.R.; Hengstman G.J.D.; Herbert J.; Herring M.; Hodgkinson S.; Hoffmann O.M.; Hofmann W.E.; Honeycutt W.D.; Hua L.H.; Huang D.; Huang Y.; Huang D.; Hupperts R.; Imre P.; Jacobs A.K.; Jakab G.; Jasinska E.; Kaida K.; Kalnina J.; Kaprelyan A.; Karelis G.; Karussis D.; Katz A.; Khabirov F.A.; Khatri B.; Kimura T.; Kister I.; Kizlaitiene R.; Klimova E.; Koehler J.; Komatineni A.; Kornhuber A.; Kovacs K.; Koves A.; Kozubski W.; Krastev G.; Krupp L.B.; Kurca E.; Lassek C.; Laureys G.; Lee L.; Lensch E.; Leutmezer F.; Li H.; Linker R.A.; Linnebank M.; Liskova P.; Llanera C.; Lu J.; Lutterotti A.; Lycke J.; Macdonell R.; Maciejowski M.; Maeurer M.; Magzhanov R.V.; Maida E.-M.; Malciene L.; Mao-Draayer Y.; Marfia G.A.; Markowitz C.; Mastorodimos V.; Matyas K.; Meca-Lallana J.; Merino J.A.G.; Mihetiu I.G.; Milanov I.; Miller A.E.; Millers A.; Mirabella M.; Mizuno M.; Montalban X.; Montoya L.; Mori M.; Mueller S.; Nakahara J.; Nakatsuji Y.; Newsome S.; Nicholas R.; Nielsen A.S.; Nikfekr E.; Nocentini U.; Nohara C.; Nomura K.; Odinak M.M.; Olsson T.; van Oosten B.W.; Oreja-Guevara C.; Oschmann P.; Overell J.; Pachner A.; Panczel G.; Pandolfo M.; Papeix C.; Patrucco L.; Pelletier J.; Piedrabuena R.; Pless M.; Polzer U.; Pozsegovits K.; Rastenyte D.; Rauer S.; Reifschneider G.; Rey R.; Rizvi S.A.; Robertson D.; Rodriguez J.M.; Rog D.; Roshanisefat H.; Rowe V.; Rozsa C.; Rubin S.; Rusek S.; Sacca F.; Saida T.; Salgado A.V.; Sanchez V.E.F.; Sanders K.; Satori M.; Sazonov D.V.; Scarpini E.A.; Schlegel E.; Schluep M.; Schmidt S.; Scholz E.; Schrijver H.M.; Schwab M.; Schwartz R.; Scott J.; Selmaj K.; Shafer S.; Sharrack B.; Shchukin I.A.; Shimizu Y.; Shotekov P.; Siever A.; Sigel K.-O.; Silliman S.; Simo M.; Simu M.; Sinay V.; Siquier A.E.; Siva A.; Skoda O.; Solomon A.; Stangel M.; Stefoski D.; Steingo B.; Stolyarov I.D.; Stourac P.; Strassburger-Krogias K.; Strauss E.; Stuve O.; Tarnev I.; Tavernarakis A.; Tello C.R.; Terzi M.; Ticha V.; Ticmeanu M.; Tiel-Wilck K.; Toomsoo T.; Tubridy N.; Tullman M.J.; Tumani H.; Turcani P.; Turner B.; Uccelli A.; Urtaza F.J.O.; Vachova M.; Valikovics A.; Walter S.; Van Wijmeersch B.; Vanopdenbosch L.; Weber J.R.; Weiss S.; Weissert R.; Vermersch P.; West T.; Wiendl H.; Wiertlewski S.; Wildemann B.; Willekens B.; Visser L.H.; Vorobeychik G.; Xu X.; Yamamura T.; Yang Y.N.; Yelamos S.M.; Yeung M.; Zacharias A.; Zelkowitz M.; Zettl U.; Zhang M.; Zhou H.; Zieman U.; Ziemssen T.. The Lancet. 2018.

Testosterone and estrogen in multiple sclerosis: from pathophysiology to therapeutics.

Collongues N; Patte-Mensah C; De Seze J; Mensah-Nyagan AG; Derfuss T. Expert review of neurotherapeutics. 2018.

Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis.

Kappos L; Arnold DL; Bar-Or A; Camm AJ; Derfuss T; Sprenger T; Davies M; Piotrowska A; Ni P; Harada T. Multiple Sclerosis Journal. 2018.

Characterising immunological properties of dimethylfumarate treatment: Longitudinal data from MS patients

Diebold, M.; Sievers, C.; Sanderson, N.; Meira, M.; Kappos, L.; Lindberg, R. L.; Derfuss, T.. European Journal of Neurology. 2017.

Characterising properties of dimethylfumarate on innate and adaptive immunity: longitudinal data from MS patients

Diebold, M.; Sievers, C.; Sanderson, N.; Kappos, L.; Lindberg, R. L. P.; Derfuss, T.. Multiple Sclerosis Journal. 2017.

Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results.

Link J; Ramanujam R; Auer M; Ryner M; Hässler S; Bachelet D; Mbogning C; Warnke C; Buck D; Hyldgaard Jensen PE; Sievers C; Ingenhoven K; Fissolo N; Lindberg R; Grummel V; Donnellan N; Comabella M; Montalban X; Kieseier B; Soelberg Sørensen P; Hartung HP; Derfuss T; Lawton A; Sikkema D; Pallardy M; Hemmer B; Deisenhammer F; Broët P; Dönnes P; Davidson J; Fogdell-Hahn A; ABIRISK Consortium.. PLoS ONE. 2017.

Cocapture of cognate and bystander antigens can activate autoreactive B cells.

Sanderson NS; Zimmermann M; Eilinger L; Gubser C; Schaeren-Wiemers N; Lindberg RL; Dougan SK; Ploegh HL; Kappos L; Derfuss T. Proceedings of the National Academy of Sciences of the United States of America. 2017.

Comparison between central and whole brain atrophy in multiple sclerosis measured by structural image evaluation using normalization of atrophy (SIENA)

Sinnecker, T.; Ruberte, E.; Amann, M.; Naegelin, Y.; Radue, E. W.; Penner, I. K.; Kuhle, J.; Derfuss, T.; Stippich, C.; Kappos, L.; Wuerfel, J.; Yaldizli, O.. Multiple Sclerosis Journal. 2017.

Cytometry by Time of Flight (CyTOF) shows an increase of T follicular helper-like cells in the CSF of MS patients

Sanderson, N.; Johansson, D.; Rauld, C.; Raad, L.; Kappos, L.; Kuhle, J.; Carballido, J.; Derfuss, T.. Multiple Sclerosis Journal. 2017.

Daclizumab for the treatment of multiple sclerosis.

Papadopoulou A; Derfuss T; Sprenger T. Neurodegenerative Disease Management. 2017.

Expression of the Antioxidative Enzyme Peroxiredoxin 2 in Multiple Sclerosis Lesions in Relation to Inflammation.

Voigt D; Scheidt U; Derfuss T; Brück W; Junker A. International Journal of Molecular Sciences. 2017.

Fingolimod vs. dimethyl fumarate in relapsing-remitting multiple sclerosis: propensity score matched comparison in a large observational data set

Lorscheider, J.; Benkert, P.; Lienert, C.; Hanni, P.; Schmid, J.; Derfuss, T.; Kuhle, J.; Kappos, L.; Yaldizli, O.. Multiple Sclerosis Journal. 2017.

Longitudinal changes in lymphocyte subsets of siponimod-treated patients with SPMS

Bar-Or, A.; Derfuss, T.; Vermersch, P.; Gold, R.; Tomic, D.; Cheviet, S.; Rouyrre, N.; Sidorenko, T.; Hillenbrand, R.; Kappos, L.. Multiple Sclerosis Journal. 2017.

Lymphocyte recovery in real life clinical practice after discontinuation of fingolimod in patients with multiple sclerosis

Nagy, S.; Kuhle, J.; Kappos, L.; Derfuss, T.. Multiple Sclerosis Journal. 2017.

PARP-1 deregulation in MS

Meira, M.; Sievers, C.; Hoffmann, F.; Derfuss, T.; Haghikia, A.; Kuhle, J.; Kappos, L.; Lindberg, R. L. P.. Multiple Sclerosis Journal. 2017.

PML risk and natalizumab: the elephant in the room

Derfuss T.; Kappos L.. The Lancet Neurology. 2017.

Post-vaccination autoimmune CNS demyelination in a family with MOG antibodies - genes or environment?

Probstel, A. -K.; Lindner, J.; Lecourt, A. -C.; Schirmer, L.; Sabatino, J. J.; Zamvil, S. S.; Kappos, L.; Baranzini, S. E.; Traggiai, E.; Derfuss, T.. Multiple Sclerosis Journal. 2017.

Serum neurofilament light chain correlates with disease activity and predicts clinical and MRI outcomes in MS

Barro, C.; Benkert, P.; Grobke, S.; Naegelin, Y.; Disanto, G.; Amann, M.; Magon, S.; Derfuss, T.; Yaldizli, O.; Parmar, K.; Wuerfel, J.; Kappos, L.; Kuhle, J.. Multiple Sclerosis Journal. 2017.

α4-integrin receptor desaturation and disease activity return after natalizumab cessation.

Derfuss T; Kovarik JM; Kappos L; Savelieva M; Chhabra R; Thakur A; Zhang Y; Wiendl H; Tomic D. Neurology(R) neuroimmunology & neuroinflammation. 2017.

[Cell depletion and myoablation for neuroimmunological diseases].

Diebold M; Kappos L; Derfuss T. Nervenarzt. 2016.

Anti-KIR4.1 antibodies do not differentiate multiple sclerosis patients from controls

Proebstel, Anne-Katrin; Kuhle, Jens; Lecourt, Anne-Catherine; Vock, Isabelle; Sanderson, Nicholas; Kappos, Ludwig; Derfuss, Tobias. Neurology. 2016.

Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa.

Kuhle J; Barro C; Andreasson U; Derfuss T; Lindberg R; Sandelius Å; Liman V; Norgren N; Blennow K; Zetterberg H. Clinical Chemistry and Laboratory Medicine. 2016.

Disease activity return after natalizumab cessation in multiple sclerosis.

Rasenack M; Derfuss T. Expert review of neurotherapeutics. 2016.

ECTRIMS-EAN clinical practice guideline on pharmacological management of multiple sclerosis.

Otero-Romero, S.; Amato, M. P.; Chandraratna, D.; Clanet, M.; Comi, G.; Derfuss, T.; Fazekas, F.; Hemmer, B.; Hartung, H. -P.; Havrdova, E.; Kappos, L.; Liblau, R.; Lubetzki, C.; Miller, D. H.; Olsson, T.; Selmaj, C.; Siva, A.; Sorensen, P. S.; Thalheim, C.; Wiendl, H.; Zipp, F.; Thompson, A. J.; Gold, R.; Montalban, X.. Multiple Sclerosis Journal. 2016.

Efficacy and Safety of Fingolimod in an Unselected Patient Population.

Rasenack M; Rychen J; Andelova M; Naegelin Y; Stippich C; Kappos L; Lindberg RL; Sprenger T; Derfuss T. PLoS ONE. 2016.

Emerging role of extracellular vesicle-derived microRNAs/mRNAs in immune response of Multiple Sclerosis

Ritz, S.; Meira, M.; Sievers, C.; Hoffmann, F.; Kappos, L.; Derfuss, T.; Lindberg, R. L. P.. Multiple Sclerosis Journal. 2016.

Extending the spectrum of anti-MOG antibody positive autoimmune inflammatory CNS disease: overlapping demyelinating syndromes in patients with systemic lupus erythematosus

Probstel, A. -K.; Thanei, M.; Erni, B.; Lecourt, A. -C.; Branco, L.; Andre, R.; Lalive, P.; Koenig, K.; Huynh-Do, U.; Ribi, C.; Chizzolini, C.; Kappos, L.; Trendelenburg, M.; Derfuss, T.. Multiple Sclerosis Journal. 2016.

High sensitivity serum neurofilament-light chain measurements correlate with disease activity and disability in multiple sclerosis and are reduced after immunomodulatory treatment intervention.

Barro, C.; Derfuss, T.; Nagelin, Y.; Benkert, P.; Schadelin, S.; Yaldizli, O.; Achtnichts, L.; Nedeltchev, K.; Kamm, C. P.; Salmen, A.; Lalive, P. H.; Schluep, M.; Du Pasquier, R.; Muller, S.; Vehoff, J.; Norgren, N.; Zecca, C.; Disanto, G.; Gobbi, C.; Kappos, L.; Kuhle, J.. Multiple Sclerosis Journal. 2016.

Immunological treatment of multiple sclerosis.

Diebold M; Derfuss T. SEMINARS IN HEMATOLOGY. 2016.

Inflammatory Diseases of the Central and Peripheral Nervous System in Patients with Systemic Lupus Erythematosus: Autoantibody Findings and Clinical Phenotype

Proebstel, Anne-Katrin; Thanai, Madlaina; Erni, Barbara; Anne-Catherine, Lecourt; Branco, Leonore; Ribi, Camillo; Koenig, Katrin; Huynh-Do, Uyen; Chizzolini, Carlo; Kappos, Ludwig; Trendelenburg, Marten; Derfuss, Tobias. Neurology. 2016.

Interdisciplinary Risk Management in the Treatment of Multiple Sclerosis.

Havla J; Warnke C; Derfuss T; Kappos L; Hartung HP; Hohlfeld R. Deutsches Arzteblatt International. 2016.

Lateral Ventricle Volume change is associated with neurological and cognitive disability in multiple sclerosis: a 5-years follow-up study using an automated lateral ventricle segmentation algorithm

Ruberte, E.; Amann, M.; Naegelin, Y.; Penner, I. K.; Pardini, M.; Kuhle, J.; Derfuss, T.; Stippich, C.; Kappos, L.; Wuerfel, J.; Yaldizli, O.. Multiple Sclerosis Journal. 2016.

Lower relapse rates with natalizumab as compared with fingolimod as second-line treatment in relapsing-remitting multiple sclerosis

Lienert, C.; Benkert, P.; Beer, S.; Hanni, P.; Pardini, M.; D'Souza, M.; Derfuss, T.; Kuhle, J.; Kappos, L.; Yaldizli, O.. Multiple Sclerosis Journal. 2016.

Multiple Sclerosis and Antibodies against KIR4.1.

Pröbstel AK; Kuhle J; Lecourt AC; Vock I; Sanderson NS; Kappos L; Derfuss T. New England Journal of Medicine. 2016.

Natalizumab-induced POU2AF1/Spi-B upregulation: A possible route for PML development.

Meira M; Sievers C; Hoffmann F; Haghikia A; Rasenack M; Décard BF; Kuhle J; Derfuss T; Kappos L; Lindberg RL. Neurology(R) neuroimmunology & neuroinflammation. 2016.

Observational study to identify biomarkers for treatment response in dimethylfumarate treated MS patients

Diebold, M.; Sievers, C.; Sanderson, N.; Meira, M.; Kappos, L.; Lindberg, R. L. P.; Derfuss, T.. Multiple Sclerosis Journal. 2016.

Optimizing treatment success in multiple sclerosis.

Ziemssen T; Derfuss T; de Stefano N; Giovannoni G; Palavra F; Tomic D; Vollmer T; Schippling S. Journal of Neurology. 2016.

Promising Oral Compounds for the Treatment of Multiple Sclerosis: A Glance into the Future.

Décard BF; Derfuss T. Seminars in Neurology. 2016.

Relapse rates in patients with multiple sclerosis treated with fingolimod: Subgroup analyses of pooled data from three phase 3 trials.

Derfuss T; Ontaneda D; Nicholas J; Meng X; Hawker K. Multiple Sclerosis and Related Disorders. 2016.

Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial

Kappos,Ludwig; Arnold,Douglas L; Bar-Or,Amit; Camm,John; Derfuss,Tobias; Kieseier,Bernd C; Sprenger,Till; Greenough,Kristin; Ni,Pingping; Harada,Tomohiko. The Lancet Neurology. 2016.

Secretion of autoantibodies by autoreactive B cells is supported by anti-viral T cells

Sanderson, N.; Zimmermann, M.; Eilinger, L.; Lindberg, R.; Kappos, L.; Derfuss, T.. Multiple Sclerosis Journal. 2016.

Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity.

Kuhle J; Barro C; Disanto G; Mathias A; Soneson C; Bonnier G; Yaldizli Ö; Regeniter A; Derfuss T; Canales M; Schluep M; Du Pasquier R; Krueger G; Granziera C. Multiple Sclerosis Journal. 2016.

Severe exacerbation of relapsing-remitting multiple sclerosis after G-CSF therapy.

Rust H; Kuhle J; Kappos L; Derfuss T. Neurology(R) neuroimmunology & neuroinflammation. 2016.

The ACROSS study: long-term efficacy of fingolimod in patients with RRMS (Follow-up at 10 years)

Derfuss, T.; Sastre-Garriga, J.; Montalban, X.; Rodegher, M.; Gannon, G.; Bezuidenhoudt, M.; Van Hoef, M.; Silva, D.; Kappos, L.. Multiple Sclerosis Journal. 2016.

The Swiss Multiple Sclerosis Cohort-Study (SMSC): A prospective Swiss wide investigation of key phases in disease evolution and new treatment options

Disanto G.; Benkert P.; Lorscheider J.; Mueller S.; Vehoff J.; Zecca C.; Ramseier S.; Achtnichts L.; Findling O.; Nedeltchev K.; Radue E.-W.; Sprenger T.; Stippich C.; Derfuss T.; Louvion J.-F.; Kamm C.P.; Mattle H.P.; Lotter C.; Du Pasquier R.; Schluep M.; Pot C.; Lalive P.H.; Yaldizli O.; Gobbi C.; Kappos L.; Kuhle J.; Saxer J.; Remonda L.; Boxheimer L.; Limberg M.; Scheerer I.; Orleth A.; Treppke F.; Beregi E.; Reinhardt J.; Fellner I.; Wurfel J.; Thoeni A.; Palatini A.; Pauli-Magnus C.; Fabbro T.; Roesler A.; Mechati S.; Chan A.; Salmen A.; Kaeser M.; Wagner F.; Verma R.; Di Marco M.; Haller S.; Lovblad K.-O.; Granziera C.; Hagmann P.; Maeder P.; Tschuor S.; Cianfoni A.; Weber J.. PLoS ONE. 2016.

Tumefactive multiple sclerosis lesions under fingolimod: case series from an MS centre and review of phase 2 and 3 clinical trial data

Probstel, A. -K.; Radu, E. -W.; Mueller-Lenke, N.; Zhang-Auberson, L.; Bischof, D.; Merschhemke, M.; Kuhle, J.; Kappos, L.; Derfuss, T.; Decard, B.. Multiple Sclerosis Journal. 2016.

Validation of an automated lateral ventricle delineation algorithm (ALVIN) in multiple sclerosis

Ruberte, E.; Amann, M.; Naegelin, Y.; Penner, I. K.; Pardini, M.; Kuhle, J.; Derfuss, T.; Stippich, C.; Kappos, L.; Wuerfel, J.; Yaldizli, O.. Multiple Sclerosis Journal. 2016.

Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype.

Pröbstel AK; Rudolf G; Dornmair K; Collongues N; Chanson JB; Sanderson NS; Lindberg RL; Kappos L; de Seze J; Derfuss T. Journal of neuroinflammation. 2015.

A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients.

Derfuss T; Curtin F; Guebelin C; Bridel C; Rasenack M; Matthey A; Du Pasquier R; Schluep M; Desmeules J; Lang AB; Perron H; Faucard R; Porchet H; Hartung HP; Kappos L; Lalive PH. Multiple Sclerosis Journal. 2015.

A phase IIa randomized clinical study testing GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis associated endogenous retrovirus in multiple sclerosis patients - a twelve month follow-up.

Derfuss T; Curtin F; Guebelin C; Bridel C; Rasenack M; Matthey A; Du Pasquier R; Schluep M; Desmeules J; Lang AB; Perron H; Faucard R; Porchet H; Hartung HP; Kappos L; Lalive PH. Journal of Neuroimmunology. 2015.

A pragmatic approach to dealing with fingolimod-related lymphopaenia in Europe.

Giovannoni G; de Jong B; Derfuss T; Izquierdo G; Mazibrada G; Molyneux P; Nicholas R; Overell J; Ziemssen T; Juliusson G. Multiple Sclerosis and Related Disorders. 2015.

B Cells and Autoantibodies in Multiple Sclerosis.

Pröbstel AK; Sanderson NS; Derfuss T. International Journal of Molecular Sciences. 2015.

Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study.

Kuhle J; Disanto G; Dobson R; Adiutori R; Bianchi L; Topping J; Bestwick JP; Meier UC; Marta M; Dalla Costa G; Runia T; Evdoshenko E; Lazareva N; Thouvenot E; Iaffaldano P; Direnzo V; Khademi M; Piehl F; Comabella M; Sombekke M; Killestein J; Hegen H; Rauch S; D'Alfonso S; Alvarez-Cermeño JC; Kleinová P; Horáková D; Roesler R; Lauda F; Llufriu S; Avsar T; Uygunoglu U; Altintas A; Saip S; Menge T; Rajda C; Bergamaschi R; Moll N; Khalil M; Marignier R; Dujmovic I; Larsson H; Malmestrom C; Scarpini E; Fenoglio C; Wergeland S; Laroni A; Annibali V; Romano S; Martínez AD; Carra A; Salvetti M; Uccelli A; Torkildsen Ø; Myhr KM; Galimberti D; Rejdak K; Lycke J; Frederiksen JL; Drulovic J; Confavreux C; Brassat D; Enzinger C; Fuchs S; Bosca I; Pelletier J; Picard C; Colombo E; Franciotta D; Derfuss T; Lindberg R; Yaldizli Ö; Vécsei L; Kieseier BC; Hartung HP; Villoslada P; Siva A; Saiz A; Tumani H; Havrdová E; Villar LM; Leone M; Barizzone N; Deisenhammer F; Teunissen C; Montalban X; Tintoré M; Olsson T; Trojano M; Lehmann S; Castelnovo G; Lapin S; Hintzen R; Kappos L; Furlan R; Martinelli V; Comi G; Ramagopalan SV; Giovannoni G. Multiple Sclerosis Journal. 2015.

Efficacy of fingolimod in patients with highly active relapsing-remitting multiple sclerosis.

Derfuss T; Bergvall NK; Sfikas N; Tomic DL. Current Medical Research and Opinion. 2015.

Immunologic monitoring during a phase 2a trial of the GNbAC1 antibody in patients with MS

Zimmermann, Maria; Sanderson, Nicholas S. R.; Rasenack, Maria; Lalive, Patrice H.; Lang, Alois B.; Curtin, Francois; Lindberg, Raija L. P.; Kappos, Ludwig; Derfuss, Tobias. Neurology(R) neuroimmunology & neuroinflammation. 2015.

Optimizing treatment initiation: Effects of a patient education program about fingolimod treatment on knowledge, self-efficacy and patient satisfaction

Zimmer A.; Blauer C.; Coslovsky M.; Kappos L.; Derfuss T.. Multiple Sclerosis and Related Disorders. 2015.

Oral therapies for relapsing remitting multiple sclerosis

Diebold M.; Derfuss T.. Schweizer Archiv fur Neurologie und Psychiatrie. 2015.

Pro-inflammatory pattern of IgG1 Fc glycosylation in multiple sclerosis cerebrospinal fluid.

Wuhrer M; Selman MH; McDonnell LA; Kümpfel T; Derfuss T; Khademi M; Olsson T; Hohlfeld R; Meinl E; Krumbholz M. Journal of neuroinflammation. 2015.

Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS.

Kappos L; Radue EW; Comi G; Montalban X; Butzkueven H; Wiendl H; Giovannoni G; Hartung HP; Derfuss T; Naegelin Y; Sprenger T; Mueller-Lenke N; Griffiths S; von Rosenstiel P; Gottschalk R; Zhang Y; Dahlke F; Tomic D; TOFINGO study group. Neurology. 2015.

Cerebellar abnormalities contribute to disability including cognitive impairment in multiple sclerosis.

Weier K; Penner IK; Magon S; Amann M; Naegelin Y; Andelova M; Derfuss T; Stippich C; Radue EW; Kappos L; Sprenger T. PLoS ONE. 2014.

Interferon Beta and Vitamin D Synergize to Induce Immunoregulatory Receptors on Peripheral Blood Monocytes of Multiple Sclerosis Patients

Waschbisch, Anne; Sanderson, Nicholas; Krumbholz, Markus; Vlad, George; Theil, Diethilde; Schwab, Stefan; Maeurer, Mathias; Derfuss, Tobias. PLoS ONE. 2014.

MiR-126: a novel route for natalizumab action?

Meira M; Sievers C; Hoffmann F; Derfuss T; Kuhle J; Kappos L; Lindberg RL. Multiple Sclerosis Journal. 2014.

Unraveling natalizumab effects on deregulated miR-17 expression in CD4+ T cells of patients with relapsing-remitting multiple sclerosis.

Meira M; Sievers C; Hoffmann F; Rasenack M; Kuhle J; Derfuss T; Kappos L; Lindberg RL. Journal of Immunology Research. 2014.

[What's new in multiple sclerosis therapy?].

Vaney C; Derfuss T. Revue Medicale Suisse. 2013.

Aquaporin-4 antibody negative recurrent isolated optic neuritis: clinical evidence for disease heterogeneity.

Waschbisch A; Atiya M; Schaub C; Derfuss T; Schwab S; Lee DH; Müller M; Linker RA. Journal of the neurological sciences. 2013.

Natalizumab therapy for multiple sclerosis.

Derfuss T; Kuhle J; Lindberg R; Kappos L. Seminars in Neurology. 2013.

Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis.

Kuhle J; Malmeström C; Axelsson M; Plattner K; Yaldizli O; Derfuss T; Giovannoni G; Kappos L; Lycke J. Acta neurologica Scandinavica. 2013.

Neurologist-in-training: Multiple sclerosis

Yaldizli O.; Kuhle J.; Derfuss T.; Sprenger T.; Kappos L.. Schweizer Archiv fur Neurologie und Psychiatrie. 2013.

Predicting PML in natalizumab-treated patients: can we do better?

Derfuss T; Kappos L. Journal of Neurology, Neurosurgery and Psychiatry. 2013.

Recommendations for the use of prolonged-release fampridine in patients with multiple sclerosis (MS).

Preiningerova JL; Baumhackl U; Csepany T; Czaplinski A; Deisenhammer F; Derfuss T; Fabjan TH; Fazekas F; Fuchs S; Havrdova E; Ledinek AH; Illes Z; Jazbec SS; Klimova E; Komoly S; Kurca E; Linnebank M; Lisy L; Mares J; Prochazkova L; Csilla R; Szilasiova J; Stourac P; Talab R; Turcani P; Vachova M; Vecsei L; Vodusek D; Zapletalova O; Berger T. CNS Neuroscience & Therapeutics. 2013.

T-cell response against varicella-zoster virus in fingolimod-treated MS patients.

Ricklin,Meret E; Lorscheider,Johannes; Waschbisch,Anne; Paroz,Cecile; Mehta,Satish K; Pierson,Duane L; Kuhle,Jens; Fischer-Barnicol,Bettina; Sprenger,Till; Lindberg,Raija L P; Kappos,Ludwig; Derfuss,Tobias. Neurology. 2013.

What's new in the causal treatment of multiple sclerosis? Was gibt's Neues in der kausalen Behandlung der Multiplen Sklerose?

Vaney C.; Derfuss T.. Revue Medicale Suisse. 2013.

B cells and antibodies in multiple sclerosis pathogenesis and therapy.

Krumbholz M; Derfuss T; Hohlfeld R; Meinl E. Nature reviews. Neurology. 2012.

Clonal expansions of CD8⁺ T cells in latently HSV-1-infected human trigeminal ganglia.

Held K; Eiglmeier I; Himmelein S; Sinicina I; Brandt T; Theil D; Dornmair K; Derfuss T. Journal of neurovirology. 2012.

Evaluating the potential benefit of interferon treatment in multiple sclerosis.

Derfuss T; Kappos L. JAMA - Journal of the American Medical Association. 2012.

Evaluation of a new approach for semi-automatic segmentation of the cerebellum in patients with multiple sclerosis.

Weier K; Beck A; Magon S; Amann M; Naegelin Y; Penner IK; Thürling M; Aurich V; Derfuss T; Radue EW; Stippich C; Kappos L; Timmann D; Sprenger T. Journal of Neurology. 2012.

Identifying autoantigens in demyelinating diseases: valuable clues to diagnosis and treatment?

Derfuss T; Meinl E. Current Opinion in Neurology. 2012.

Neurofascin as a target for autoantibodies in peripheral neuropathies.

Ng JK; Malotka J; Kawakami N; Derfuss T; Khademi M; Olsson T; Linington C; Odaka M; Tackenberg B; Prüss H; Schwab JM; Harms L; Harms H; Sommer C; Rasband MN; Eshed-Eisenbach Y; Peles E; Hohlfeld R; Yuki N; Dornmair K; Meinl E. Neurology. 2012.

Personalized medicine in multiple sclerosis: hope or reality?

Derfuss T. BMC Medicine. 2012.

Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis.

Pröbstel AK; Dornmair K; Bittner R; Sperl P; Jenne D; Magalhaes S; Villalobos A; Breithaupt C; Weissert R; Jacob U; Krumbholz M; Kuempfel T; Blaschek A; Stark W; Gärtner J; Pohl D; Rostasy K; Weber F; Forne I; Khademi M; Olsson T; Brilot F; Tantsis E; Dale RC; Wekerle H; Hohlfeld R; Banwell B; Bar-Or A; Meinl E; Derfuss T. Neurology. 2011.

Control of HSV-1 latency in human trigeminal ganglia--current overview.

Held K; Derfuss T. Journal of neurovirology. 2011.

Expression of herpes simplex virus 1-encoded microRNAs in human trigeminal ganglia and their relation to local T-cell infiltrates.

Held K; Junker A; Dornmair K; Meinl E; Sinicina I; Brandt T; Theil D; Derfuss T. Journal of Virology. 2011.

Fingolimod for multiple sclerosis: mechanism of action, clinical outcomes, and future directions.

Mehling M; Kappos L; Derfuss T. Current neurology and neuroscience reports. 2011.

Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis.

Waschbisch A; Atiya M; Linker RA; Potapov S; Schwab S; Derfuss T. PLoS ONE. 2011.

Humoral autoimmunity in multiple sclerosis.

Meinl E; Derfuss T; Krumbholz M; Pröbstel AK; Hohlfeld R. Journal of the neurological sciences. 2011.

Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS.

Kuhle J; Gosert R; Bühler R; Derfuss T; Sutter R; Yaldizli O; Radue EW; Ryschkewitsch C; Major EO; Kappos L; Frank S; Hirsch HH. Neurology. 2011.

Neurologist-in-training

Yaldizli O.; Kuhle J.; Derfuss T.; Sprenger T.; Kappos L.. Schweizer Archiv fur Neurologie und Psychiatrie. 2011.

Axo-glial antigens as targets in multiple sclerosis: implications for axonal and grey matter injury.

Derfuss T; Linington C; Hohlfeld R; Meinl E. Journal of molecular medicine (Berlin, Germany). 2010.

Latency of herpes simplex virus type-1 in human geniculate and vestibular ganglia is associated with infiltration of CD8+ T cells.

Arbusow V; Derfuss T; Held K; Himmelein S; Strupp M; Gurkov R; Brandt T; Theil D. Journal of Medical Virology. 2010.

Mitochondrial cytochrome redox states and respiration in acute pulmonary oxygen sensing.

Sommer N; Pak O; Schörner S; Derfuss T; Krug A; Gnaiger E; Ghofrani HA; Schermuly RT; Huckstorf C; Seeger W; Grimminger F; Weissmann N. European Respiratory Journal. 2010.

Non-paraneoplastic limbic encephalitis associated with NMDAR and VGKC antibodies.

Pellkofer HL; Kuempfel T; Jacobson L; Vincent A; Derfuss T. Journal of Neurology, Neurosurgery and Psychiatry. 2010.

Contactin-2/TAG-1-directed autoimmunity is identified in multiple sclerosis patients and mediates gray matter pathology in animals.

Derfuss T; Parikh K; Velhin S; Braun M; Mathey E; Krumbholz M; Kümpfel T; Moldenhauer A; Rader C; Sonderegger P; Pöllmann W; Tiefenthaller C; Bauer J; Lassmann H; Wekerle H; Karagogeos D; Hohlfeld R; Linington C; Meinl E. Proceedings of the National Academy of Sciences of the United States of America. 2009.

Fewer latent herpes simplex virus type 1 and cytotoxic T cells occur in the ophthalmic division than in the maxillary and mandibular divisions of the human trigeminal ganglion and nerve.

Hüfner K; Horn A; Derfuss T; Glon C; Sinicina I; Arbusow V; Strupp M; Brandt T; Theil D. Journal of Virology. 2009.

The presence of lytic HSV-1 transcripts and clonally expanded T cells with a memory effector phenotype in human sensory ganglia.

Derfuss T; Arbusow V; Strupp M; Brandt T; Theil D. Annals of the New York Academy of Sciences. 2009.

Compartmentalization of inflammation in the CNS: a major mechanism driving progressive multiple sclerosis.

Meinl E; Krumbholz M; Derfuss T; Junker A; Hohlfeld R. Journal of the neurological sciences. 2008.

Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity.

Krumbholz M; Faber H; Steinmeyer F; Hoffmann LA; Kümpfel T; Pellkofer H; Derfuss T; Ionescu C; Starck M; Hafner C; Hohlfeld R; Meinl E. Brain. 2008.

Targeting myelin proteolipid protein to the MHC class I pathway by ubiquitination modulates the course of experimental autoimmune encephalomyelitis.

Theil DJ; Libbey JE; Rodriguez F; Whitton JL; Tsunoda I; Derfuss TJ; Fujinami RS. Journal of Neuroimmunology. 2008.

CCL19 is constitutively expressed in the CNS, up-regulated in neuroinflammation, active and also inactive multiple sclerosis lesions.

Krumbholz M; Theil D; Steinmeyer F; Cepok S; Hemmer B; Hofbauer M; Farina C; Derfuss T; Junker A; Arzberger T; Sinicina I; Hartle C; Newcombe J; Hohlfeld R; Meinl E. Journal of Neuroimmunology. 2007.

Neurofascin as a novel target for autoantibody-mediated axonal injury.

Mathey EK; Derfuss T; Storch MK; Williams KR; Hales K; Woolley DR; Al-Hayani A; Davies SN; Rasband MN; Olsson T; Moldenhauer A; Velhin S; Hohlfeld R; Meinl E; Linington C. Journal of Experimental Medicine. 2007.

Presence of HSV-1 immediate early genes and clonally expanded T-cells with a memory effector phenotype in human trigeminal ganglia.

Derfuss T; Segerer S; Herberger S; Sinicina I; Hüfner K; Ebelt K; Knaus HG; Steiner I; Meinl E; Dornmair K; Arbusow V; Strupp M; Brandt T; Theil D. Brain pathology (Zurich, Switzerland). 2007.

The prevalence of human herpesvirus 6 in human sensory ganglia and its co-occurrence with alpha-herpesviruses.

Hüfner K; Arbusow V; Himmelein S; Derfuss T; Sinicina I; Strupp M; Brandt T; Theil D. Journal of neurovirology. 2007.

Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment.

Krumbholz M; Theil D; Cepok S; Hemmer B; Kivisäkk P; Ransohoff RM; Hofbauer M; Farina C; Derfuss T; Hartle C; Newcombe J; Hohlfeld R; Meinl E. Brain. 2006.

Latency of alpha-herpes viruses is accompanied by a chronic inflammation in human trigeminal ganglia but not in dorsal root ganglia.

Hüfner K; Derfuss T; Herberger S; Sunami K; Russell S; Sinicina I; Arbusow V; Strupp M; Brandt T; Theil D. Journal of Neuropathology and Experimental Neurology. 2006.

BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma.

Krumbholz M; Theil D; Derfuss T; Rosenwald A; Schrader F; Monoranu CM; Kalled SL; Hess DM; Serafini B; Aloisi F; Wekerle H; Hohlfeld R; Meinl E. Journal of Experimental Medicine. 2005.

Expression and function of glial cell line-derived neurotrophic factor family ligands and their receptors on human immune cells.

Vargas-Leal V; Bruno R; Derfuss T; Krumbholz M; Hohlfeld R; Meinl E. Journal of Immunology. 2005.

Immunoadsorption patients with multiple sclerosis: an open-label pilot study.

Moldenhauer A; Haas J; Wäscher C; Derfuss T; Hoffmann KT; Kiesewetter H; Salama A. European Journal of Clinical Investigation. 2005.

Intrathecal antibody (IgG) production against human herpesvirus type 6 occurs in about 20% of multiple sclerosis patients and might be linked to a polyspecific B-cell response.

Derfuss T; Hohlfeld R; Meinl E. Journal of Neurology. 2005.

Prevalence and distribution of HSV-1, VZV, and HHV-6 in human cranial nerve nuclei III, IV, VI, VII, and XII.

Theil D; Horn AK; Derfuss T; Strupp M; Arbusow V; Brandt T. Journal of Medical Virology. 2004.

Dually infected (HSV-1/VZV) single neurons in human trigeminal ganglia.

Theil D; Paripovic I; Derfuss T; Herberger S; Strupp M; Arbusow V; Brandt T. Annals of Neurology. 2003.

Latent herpesvirus infection in human trigeminal ganglia causes chronic immune response.

Theil D; Derfuss T; Paripovic I; Herberger S; Meinl E; Schueler O; Strupp M; Arbusow V; Brandt T. American Journal of Pathology. 2003.

Cranial nerve palsies: herpes simplex virus type 1 and varizella-zoster virus latency.

Theil D; Derfuss T; Strupp M; Gilden DH; Arbusow V; Brandt T. . 2002.

Herpesviral proteins regulating apoptosis.

Derfuss T; Meinl E. Current Topics in Microbiology and Immunology. 2002.

Simultaneous measurement of local cortical blood flow and tissue oxygen saturation by Near infra-red Laser Doppler flowmetry and remission spectroscopy in the pig brain.

Walter B; Bauer R; Krug A; Derfuss T; Traichel F; Sommer N. Acta neurochirurgica. Supplement. 2002.

[Multiple sclerosis. Chlamydia hypothesis in debate].

Derfuss T; Hohlfeld R; Meinl E. Nervenarzt. 2001.

Herpesvirus saimiri replaces ZAP-70 for CD3- and CD2-mediated T cell activation.

Meinl E; Derfuss T; Pirzer R; Blank N; Lengenfelder D; Blancher A; Le Deist F; Fleckenstein B; Hivroz C. Journal of Biological Chemistry. 2001.

Intrathecal antibody production against Chlamydia pneumoniae in multiple sclerosis is part of a polyspecific immune response.

Derfuss T; Gürkov R; Then Bergh F; Goebels N; Hartmann M; Barz C; Wilske B; Autenrieth I; Wick M; Hohlfeld R; Meinl E. Brain. 2001.

Prevalence of HSV-1 LAT in human trigeminal, geniculate, and vestibular ganglia and its implication for cranial nerve syndromes.

Theil D; Arbusow V; Derfuss T; Strupp M; Pfeiffer M; Mascolo A; Brandt T. Brain pathology (Zurich, Switzerland). 2001.

Signaling lymphocytic activation molecule (SLAM) regulates T cellular cytotoxicity.

Henning G; Kraft MS; Derfuss T; Pirzer R; de Saint-Basile G; Aversa G; Fleckenstein B; Meinl E. European Journal of Immunology. 2001.

Alterations in cytokine but not chemokine mRNA expression during three distinct Theiler's virus infections.

Theil DJ; Tsunoda I; Libbey JE; Derfuss TJ; Fujinami RS. Journal of Neuroimmunology. 2000.

Antiapoptotic activity of the herpesvirus saimiri-encoded Bcl-2 homolog: stabilization of mitochondria and inhibition of caspase-3-like activity.

Derfuss T; Fickenscher H; Kraft MS; Henning G; Lengenfelder D; Fleckenstein B; Meinl E. Journal of Virology. 1998.